Logo image of ESF0.DE

EUROFINS SCIENTIFIC (ESF0.DE) Stock Fundamental Analysis

FRA:ESF0 - Deutsche Boerse Ag - FR0014000MR3 - Common Stock - Currency: EUR

55.42  +0.16 (+0.29%)

Fundamental Rating

6

Overall ESF0 gets a fundamental rating of 6 out of 10. We evaluated ESF0 against 16 industry peers in the Life Sciences Tools & Services industry. While ESF0 has a great profitability rating, there are some minor concerns on its financial health. ESF0 is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

ESF0 had positive earnings in the past year.
In the past year ESF0 had a positive cash flow from operations.
In the past 5 years ESF0 has always been profitable.
In the past 5 years ESF0 always reported a positive cash flow from operatings.
ESF0.DE Yearly Net Income VS EBIT VS OCF VS FCFESF0.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

1.2 Ratios

ESF0 has a better Return On Assets (3.24%) than 68.75% of its industry peers.
With a decent Return On Equity value of 6.61%, ESF0 is doing good in the industry, outperforming 68.75% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 9.18%, ESF0 belongs to the top of the industry, outperforming 81.25% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for ESF0 is in line with the industry average of 6.90%.
The last Return On Invested Capital (9.18%) for ESF0 is above the 3 year average (8.70%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 3.24%
ROE 6.61%
ROIC 9.18%
ROA(3y)3.79%
ROA(5y)5.05%
ROE(3y)7.94%
ROE(5y)10.72%
ROIC(3y)8.7%
ROIC(5y)10.54%
ESF0.DE Yearly ROA, ROE, ROICESF0.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15

1.3 Margins

With a decent Profit Margin value of 5.08%, ESF0 is doing good in the industry, outperforming 62.50% of the companies in the same industry.
In the last couple of years the Profit Margin of ESF0 has grown nicely.
ESF0 has a better Operating Margin (14.97%) than 68.75% of its industry peers.
In the last couple of years the Operating Margin of ESF0 has grown nicely.
ESF0 has a Gross Margin of 22.33%. This is in the lower half of the industry: ESF0 underperforms 75.00% of its industry peers.
In the last couple of years the Gross Margin of ESF0 has grown nicely.
Industry RankSector Rank
OM 14.97%
PM (TTM) 5.08%
GM 22.33%
OM growth 3Y-11.93%
OM growth 5Y3.56%
PM growth 3Y-23.05%
PM growth 5Y9.75%
GM growth 3Y-7.6%
GM growth 5Y1.83%
ESF0.DE Yearly Profit, Operating, Gross MarginsESF0.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15 20 25

5

2. Health

2.1 Basic Checks

ESF0 has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for ESF0 has been reduced compared to 1 year ago.
Compared to 5 years ago, ESF0 has more shares outstanding
ESF0 has a better debt/assets ratio than last year.
ESF0.DE Yearly Shares OutstandingESF0.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
ESF0.DE Yearly Total Debt VS Total AssetsESF0.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B

2.2 Solvency

ESF0 has an Altman-Z score of 2.64. This is not the best score and indicates that ESF0 is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.64, ESF0 is in line with its industry, outperforming 50.00% of the companies in the same industry.
The Debt to FCF ratio of ESF0 is 4.57, which is a neutral value as it means it would take ESF0, 4.57 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of ESF0 (4.57) is better than 75.00% of its industry peers.
A Debt/Equity ratio of 0.59 indicates that ESF0 is somewhat dependend on debt financing.
ESF0 has a better Debt to Equity ratio (0.59) than 68.75% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.59
Debt/FCF 4.57
Altman-Z 2.64
ROIC/WACC1.23
WACC7.49%
ESF0.DE Yearly LT Debt VS Equity VS FCFESF0.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B 5B

2.3 Liquidity

ESF0 has a Current Ratio of 1.16. This is a normal value and indicates that ESF0 is financially healthy and should not expect problems in meeting its short term obligations.
ESF0 has a Current ratio of 1.16. This is in the lower half of the industry: ESF0 underperforms 75.00% of its industry peers.
ESF0 has a Quick Ratio of 1.09. This is a normal value and indicates that ESF0 is financially healthy and should not expect problems in meeting its short term obligations.
ESF0 has a Quick ratio (1.09) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.16
Quick Ratio 1.09
ESF0.DE Yearly Current Assets VS Current LiabilitesESF0.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 40.63% over the past year.
ESF0 shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 18.34% yearly.
Looking at the last year, ESF0 shows a small growth in Revenue. The Revenue has grown by 6.70% in the last year.
The Revenue has been growing by 8.78% on average over the past years. This is quite good.
EPS 1Y (TTM)40.63%
EPS 3Y-21.42%
EPS 5Y18.34%
EPS Q2Q%13.46%
Revenue 1Y (TTM)6.7%
Revenue growth 3Y1.14%
Revenue growth 5Y8.78%
Sales Q2Q%6.87%

3.2 Future

ESF0 is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.23% yearly.
Based on estimates for the next years, ESF0 will show a small growth in Revenue. The Revenue will grow by 6.02% on average per year.
EPS Next Y15.29%
EPS Next 2Y14.58%
EPS Next 3Y14%
EPS Next 5Y14.23%
Revenue Next Year6.83%
Revenue Next 2Y6.74%
Revenue Next 3Y6.77%
Revenue Next 5Y6.02%

3.3 Evolution

The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ESF0.DE Yearly Revenue VS EstimatesESF0.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2B 4B 6B 8B
ESF0.DE Yearly EPS VS EstimatesESF0.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2 4 6

5

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 30.79, the valuation of ESF0 can be described as expensive.
Compared to the rest of the industry, the Price/Earnings ratio of ESF0 is on the same level as its industry peers.
ESF0's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 28.18.
With a Price/Forward Earnings ratio of 15.56, ESF0 is valued correctly.
Based on the Price/Forward Earnings ratio, ESF0 is valued cheaper than 87.50% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of ESF0 to the average of the S&P500 Index (20.81), we can say ESF0 is valued slightly cheaper.
Industry RankSector Rank
PE 30.79
Fwd PE 15.56
ESF0.DE Price Earnings VS Forward Price EarningsESF0.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

93.75% of the companies in the same industry are more expensive than ESF0, based on the Enterprise Value to EBITDA ratio.
100.00% of the companies in the same industry are more expensive than ESF0, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 12.77
EV/EBITDA 7.56
ESF0.DE Per share dataESF0.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates ESF0 does not grow enough to justify the current Price/Earnings ratio.
The decent profitability rating of ESF0 may justify a higher PE ratio.
A more expensive valuation may be justified as ESF0's earnings are expected to grow with 14.00% in the coming years.
PEG (NY)2.01
PEG (5Y)1.68
EPS Next 2Y14.58%
EPS Next 3Y14%

5

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 1.08%, ESF0 has a reasonable but not impressive dividend return.
Compared to an average industry Dividend Yield of 0.82, ESF0 pays a better dividend. On top of this ESF0 pays more dividend than 81.25% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.45, ESF0's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 1.08%

5.2 History

On average, the dividend of ESF0 grows each year by 16.51%, which is quite nice.
Dividend Growth(5Y)16.51%
Div Incr Years0
Div Non Decr Years1
ESF0.DE Yearly Dividends per shareESF0.DE Yearly Dividends per shareYearly Dividends per share 2022 2023 2024 2025 0.2 0.4 0.6 0.8

5.3 Sustainability

ESF0 pays out 27.77% of its income as dividend. This is a sustainable payout ratio.
ESF0's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP27.77%
EPS Next 2Y14.58%
EPS Next 3Y14%
ESF0.DE Yearly Income VS Free CF VS DividendESF0.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B
ESF0.DE Dividend Payout.ESF0.DE Dividend Payout, showing the Payout Ratio.ESF0.DE Dividend Payout.PayoutRetained Earnings

EUROFINS SCIENTIFIC

FRA:ESF0 (5/2/2025, 7:00:00 PM)

55.42

+0.16 (+0.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)04-23 2025-04-23
Earnings (Next)07-24 2025-07-24
Inst Owners33.4%
Inst Owner ChangeN/A
Ins Owners0%
Ins Owner ChangeN/A
Market Cap10.10B
Analysts68.89
Price Target58.28 (5.16%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.08%
Yearly Dividend0.52
Dividend Growth(5Y)16.51%
DP27.77%
Div Incr Years0
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.37%
PT rev (3m)-2.99%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)2.3%
EPS NY rev (3m)1.17%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.67%
Revenue NY rev (3m)-0.73%
Valuation
Industry RankSector Rank
PE 30.79
Fwd PE 15.56
P/S 1.45
P/FCF 12.77
P/OCF 7.65
P/B 1.89
P/tB N/A
EV/EBITDA 7.56
EPS(TTM)1.8
EY3.25%
EPS(NY)3.56
Fwd EY6.43%
FCF(TTM)4.34
FCFY7.83%
OCF(TTM)7.24
OCFY13.06%
SpS38.16
BVpS29.31
TBVpS-1.59
PEG (NY)2.01
PEG (5Y)1.68
Profitability
Industry RankSector Rank
ROA 3.24%
ROE 6.61%
ROCE 11.86%
ROIC 9.18%
ROICexc 9.87%
ROICexgc 31.79%
OM 14.97%
PM (TTM) 5.08%
GM 22.33%
FCFM 11.37%
ROA(3y)3.79%
ROA(5y)5.05%
ROE(3y)7.94%
ROE(5y)10.72%
ROIC(3y)8.7%
ROIC(5y)10.54%
ROICexc(3y)9.52%
ROICexc(5y)11.6%
ROICexgc(3y)31.02%
ROICexgc(5y)39.55%
ROCE(3y)11.31%
ROCE(5y)13.7%
ROICexcg growth 3Y-18.17%
ROICexcg growth 5Y3.78%
ROICexc growth 3Y-15.5%
ROICexc growth 5Y6.63%
OM growth 3Y-11.93%
OM growth 5Y3.56%
PM growth 3Y-23.05%
PM growth 5Y9.75%
GM growth 3Y-7.6%
GM growth 5Y1.83%
F-Score8
Asset Turnover0.64
Health
Industry RankSector Rank
Debt/Equity 0.59
Debt/FCF 4.57
Debt/EBITDA 1.81
Cap/Depr 76.4%
Cap/Sales 7.6%
Interest Coverage 9.11
Cash Conversion 76.13%
Profit Quality 224%
Current Ratio 1.16
Quick Ratio 1.09
Altman-Z 2.64
F-Score8
WACC7.49%
ROIC/WACC1.23
Cap/Depr(3y)89.21%
Cap/Depr(5y)85.64%
Cap/Sales(3y)8.63%
Cap/Sales(5y)7.99%
Profit Quality(3y)162.79%
Profit Quality(5y)158.88%
High Growth Momentum
Growth
EPS 1Y (TTM)40.63%
EPS 3Y-21.42%
EPS 5Y18.34%
EPS Q2Q%13.46%
EPS Next Y15.29%
EPS Next 2Y14.58%
EPS Next 3Y14%
EPS Next 5Y14.23%
Revenue 1Y (TTM)6.7%
Revenue growth 3Y1.14%
Revenue growth 5Y8.78%
Sales Q2Q%6.87%
Revenue Next Year6.83%
Revenue Next 2Y6.74%
Revenue Next 3Y6.77%
Revenue Next 5Y6.02%
EBIT growth 1Y23.67%
EBIT growth 3Y-10.93%
EBIT growth 5Y12.66%
EBIT Next Year87.36%
EBIT Next 3Y30.94%
EBIT Next 5Y22.77%
FCF growth 1Y68.95%
FCF growth 3Y-7.69%
FCF growth 5Y25.62%
OCF growth 1Y29.56%
OCF growth 3Y-4.44%
OCF growth 5Y14.24%